A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Study Summary

This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.

Conditions

PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Interventions / Drugs

RP-A601

View on ClinicalTrials.gov ↗

Sponsor

RCKT

Rocket Pharmaceuticals

Gene Therapy

C51/100

Study Details

Enrollment9 participants

Primary Completion—

Lead SponsorRocket Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:25:37.504895+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.